ReviewAnnals of gastroenterology2021
Currently available treatment options for neuroendocrine liver metastases.
Review in Annals of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Neuroendocrine liver metastasis.Hepatobiliary surgery and nutrition · 2025Article
- Machine learning predicts prognosis in patients with gastroenteropancreatic neuroendocrine tumors with liver metastases.Discover oncology · 2025Article
- Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute.Endocrine oncology (Bristol, England) · 2025Article
- A Catalog Technique for Hepatic Cytoreductive Interventions in Patients With NETs: Aid for the Future Multidisciplinary Team.Annals of surgical oncology · 2024Article
- Liver metastases in high-grade neuroendocrine neoplasms: A comparative study of hepatic tumor volume and biochemical findings in NET G3 versus NEC.Journal of neuroendocrinology · 2024Article
- Current Management of Neuroendocrine Tumour Liver Metastases.Current oncology reports · 2024Review
- Imaging for Interventional Radiology Liver-Directed Therapies for Neuroendocrine Liver Metastases.Seminars in interventional radiology · 2024Review
- Factors Affecting Survival Outcomes in Neuroendocrine Tumor of the Appendix over the Past Two Decades.Diseases (Basel, Switzerland) · 2024Article
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- Predictors of Long-Term Outcomes After Liver Transplantation for Unresectable Metastatic Neuroendocrine Tumors.Annals of transplantation · 2023Article
- The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors.Current treatment options in oncology · 2023Review
- Review
- [Liver metastases of neuroendocrine tumors].Chirurgie (Heidelberg, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms (NEN) are frequently characterized by a high propensity for metastasis to the liver, which appears to be a dominant site of distant-stage disease, affecting quality of life and overall survival. Liver surgery with the intention to cure is the treatment of choice for resectable neuroendocrine liver metastases (NELM), aiming to potentially prolong survival and ameliorate hormonal symptoms refractory to medical control. Surgical resection is indicated for patients with NELM from well-differentiated NEN, while its feasibility and complexity are largely dictated by the degree of liver involvement. As a result of advances in surgical techniques over the past decades, complex 1- and 2-stage, or repeat liver resections are performed safely and effectively by experienced surgeons. Furthermore, liver transplantation for the treatment of NELM should be anchored in a multimodal and multidisciplinary therapeutic strategy and restricted only to highly selected individual cases. A broad spectrum of interventional radiology treatments for NELM have recently been available, with expanding indications that are more applicable, as they are less limited by patient- and tumor-related parameters, being therefore important adjuncts or alternatives to surgery. Overall, liver-targeted treatment modalities may precede the administration of systemic molecular targeted agents and chemotherapy for patients with liver-dominant metastatic disease; these appear to be a crucial component of multimodal management of patients with NEN. In the present review, we discuss surgical and non-surgical liver-targeted treatment approaches for NELM, each complementing the other, with a view to assisting physicians in optimizing multimodal NEN patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.